rituximab
Showing 26 - 50 of 2,665
Waldenstrom Macroglobulinemia Trial (Venetoclax; Rituximab, DRC)
Not yet recruiting
- Waldenstrom Macroglobulinemia
- Venetoclax; Rituximab
- DRC
- (no location specified)
Nov 4, 2022
Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +5 more
- Atezolizumab
- +9 more
-
Duarte, California
- +3 more
Nov 17, 2022
Idiopathic Membranous Nephropathy Trial in Beijing (Rituximab, Modified Ponticelli regimen)
Recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- Modified Ponticelli regimen
-
Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Mar 23, 2023
Waldenström's Macroglobulinemia Trial (zanubrutinib,bendamustine,rituximab)
Not yet recruiting
- Waldenström's Macroglobulinemia
- (no location specified)
Aug 4, 2023
Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)
Not yet recruiting
- Follicular Lymphoma
- Low Grade Non-Hodgkin's Lymphoma, Adult
- Epcoritamab
- Rituximab
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome Trial in Paris (single infusion of Rituximab, single
Not yet recruiting
- Steroid-Dependent Nephrotic Syndrome
- Steroid-Sensitive Nephrotic Syndrome
- single infusion of Rituximab
- single infusion of Obinutuzumab
-
Paris, FranceRobert Debre Hospital
Mar 14, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Carboplatin
- +5 more
-
Jacksonville, Florida
- +11 more
Jan 12, 2023
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rituximab
- Zanubrutinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)
Not yet recruiting
- OR Regimen Refractory Marginal Zone Lymphoma
- obrutinib, rituximab
- (no location specified)
Nov 12, 2023
Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive
Active, not recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- fractionated first dose rituximab
-
Geneva, SwitzerlandUniversity Hospital Geneva
Apr 21, 2023
Nefopam Trial (Nefopam ampule, diphenhydramine ampule)
Not yet recruiting
- Nefopam
- Nefopam ampule
- diphenhydramine ampule
- (no location specified)
Dec 13, 2022
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)
Recruiting
- Follicular Lymphoma
- +2 more
- Rituximab
- Copanlisib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Chronic GVHD Trial in Atlanta (Belumosudil, Rituximab)
Not yet recruiting
- Chronic Graft Versus Host Disease
- Belumosudil
- Rituximab
-
Atlanta, GeorgiaNorthside Hospital
Sep 21, 2023
Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Oct 31, 2022
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)
Not yet recruiting
- Large B-cell Lymphoma
- Prednisone
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 19, 2023
Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)
Active, not recruiting
- Post-transplant Lymphoproliferative Disorder
- Rituximab
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Jan 16, 2023
Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 26, 2022
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Trial in Rozzano (Rituximab)
Active, not recruiting
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Rituximab
-
Rozzano, Milano, ItalyIstituto Clinico Humanitas
May 17, 2023
Membranous Nephropathy - PLA2R Induced Trial in Saint Petersburg (Rituximab, Cyclophosphamide, and Corticosteroids)
Recruiting
- Membranous Nephropathy - PLA2R Induced
- Rituximab, Cyclophosphamide, and Corticosteroids
-
Saint Petersburg, Russian FederationSt. Petersburg State Pavlov Medical University
Jan 7, 2023
Glomerulonephritis, Membranous, Nephrotic Syndrome,Idiopathic Trial in Japan (Rituximab (genetical recombination), Placebo)
Not yet recruiting
- Glomerulonephritis, Membranous
- Nephrotic Syndrome,Idiopathic
- Rituximab (genetical recombination)
- Placebo
-
Anjo, Aichi, Japan
- +7 more
Jun 13, 2023
Pemphigus, Dermatologic Disease Trial (RiTUXimab Injection)
Not yet recruiting
- Pemphigus
- Dermatologic Disease
- RiTUXimab Injection
- (no location specified)
Jun 7, 2023
Rheumatic Heart Disease in Children Trial (Rituximab added to standard of care treatment, standard of care treatment)
Not yet recruiting
- Rheumatic Heart Disease in Children
- Rituximab added to standard of care treatment
- standard of care treatment
- (no location specified)
Jan 3, 2023